Equities analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report sales of $5.43 billion for the current quarter, Zacks reports. Nine analysts have issued estimates for Gilead Sciences’ earnings, with the highest sales estimate coming in at $5.59 billion and the lowest estimate coming in at $5.21 billion. Gilead Sciences reported sales of $6.51 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 16.6%. The company is scheduled to announce its next earnings results after the market closes on Thursday, October 25th.
On average, analysts expect that Gilead Sciences will report full-year sales of $21.64 billion for the current financial year, with estimates ranging from $21.02 billion to $22.27 billion. For the next year, analysts expect that the company will report sales of $21.75 billion, with estimates ranging from $19.75 billion to $23.05 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm had revenue of $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the business posted $2.56 EPS. The business’s revenue was down 20.9% compared to the same quarter last year.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 150,000 shares of company stock valued at $11,502,500. 1.16% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in GILD. NEXT Financial Group Inc boosted its stake in Gilead Sciences by 75.0% during the 1st quarter. NEXT Financial Group Inc now owns 6,939 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 2,974 shares during the last quarter. Atlantic Trust Group LLC lifted its position in shares of Gilead Sciences by 9.4% during the 1st quarter. Atlantic Trust Group LLC now owns 185,521 shares of the biopharmaceutical company’s stock worth $13,988,000 after buying an additional 15,939 shares in the last quarter. Wesbanco Bank Inc. lifted its position in shares of Gilead Sciences by 42.8% during the 1st quarter. Wesbanco Bank Inc. now owns 37,474 shares of the biopharmaceutical company’s stock worth $2,825,000 after buying an additional 11,238 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Gilead Sciences by 19.4% during the 1st quarter. Handelsbanken Fonder AB now owns 239,870 shares of the biopharmaceutical company’s stock worth $18,084,000 after buying an additional 39,000 shares in the last quarter. Finally, WINTON GROUP Ltd lifted its position in shares of Gilead Sciences by 16.4% during the 1st quarter. WINTON GROUP Ltd now owns 7,674 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 1,079 shares in the last quarter. Institutional investors and hedge funds own 77.99% of the company’s stock.
Shares of Gilead Sciences stock opened at $74.17 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 2.92. Gilead Sciences has a 1-year low of $64.27 and a 1-year high of $89.54. The stock has a market cap of $100.09 billion, a price-to-earnings ratio of 8.78, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were paid a $0.57 dividend. The ex-dividend date was Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.07%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.